Summary & Overview
HCPCS J0885: Epoetin Alfa Injection, Non-ESRD, 1000 Units
HCPCS Level II code J0885 denotes a 1000-unit vial of epoetin alfa for non-ESRD use, an erythropoiesis-stimulating agent used to manage anemia in settings such as chemotherapy-induced anemia and other approved non-ESRD indications. Nationally, this code is important for outpatient drug billing, pharmacy benefit management, and hospital outpatient reimbursement, given epoetin alfa's role in reducing transfusion need and managing hemoglobin levels in affected patients. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise explanation of the clinical context for J0885, common sites of service for administration, and the typical service type (parenteral injection). The publication summarizes payer coverage patterns, billing benchmarks, and relevant policy considerations affecting reimbursement and prior authorization for biologic agents like epoetin alfa. Additionally, the report outlines coding practice considerations, common modifiers and billing nuances relevant to outpatient administration, and where to look for payer-specific guidance. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0885 describes Injection, epoetin alfa, (for non-esrd use), 1000 units. This code represents administration of the erythropoiesis-stimulating agent epoetin alfa when used for indications other than end-stage renal disease (non-ESRD), typically to treat anemia related to chemotherapy, certain chronic conditions, or other approved non-ESRD indications.
-
Service type: Parenteral drug administration (injection)
-
Typical site of service: Outpatient clinic, physician office, hospital outpatient department, or infusion center where injectable biologic therapies are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with symptomatic anemia secondary to chemotherapy-induced myelosuppression or chronic disease (non-ESRD). The patient presents to an outpatient oncology infusion center or physician office for administration of epoetin alfa. The clinician documents baseline hemoglobin, iron studies, and recent chemotherapy schedule. The nursing staff prepares the dose measured in units (billed per J0885 per 1000 units), performs subcutaneous or intravenous administration per prescriber orders, and monitors vital signs for immediate reaction. Follow-up includes hemoglobin checks within 2–4 weeks to guide dosing adjustments and to document medical necessity for continued therapy. Billing is submitted under the office or outpatient facility site of service with appropriate diagnosis linkage and any necessary modifiers to indicate services such as discontinued procedure, significant procedural service, or participation of assistant surgeon when applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Wasted drugs/biologicals | When part of a single-use vial is discarded and payer accepts waste billing rules. |
JZ |